285 related articles for article (PubMed ID: 33474881)
1. [A Review of Metabolic Stress and Development of Pancreatic Cancer].
Li JT; Lei MZ; Lei QY; Yin M
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jan; 52(1):5-10. PubMed ID: 33474881
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
3. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
4. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
5. Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.
Andersen HB; Ialchina R; Pedersen SF; Czaplinska D
Cancer Metastasis Rev; 2021 Dec; 40(4):1093-1114. PubMed ID: 34855109
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
7. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
Sun H; Zhang B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
[TBL] [Abstract][Full Text] [Related]
8. LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification.
Tan Z; Liu J; Xu J; Zhang B; Yu X; Wang W; Liang C
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4853-4865. PubMed ID: 36269388
[TBL] [Abstract][Full Text] [Related]
9. The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting.
Jonckheere N; Vasseur R; Van Seuningen I
Crit Rev Oncol Hematol; 2017 Mar; 111():7-19. PubMed ID: 28259298
[TBL] [Abstract][Full Text] [Related]
10. Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies.
Wang Z; Wu B; Nie G; Wei J; Li Y
Cancer Lett; 2023 Apr; 560():216138. PubMed ID: 36934836
[TBL] [Abstract][Full Text] [Related]
11. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
[TBL] [Abstract][Full Text] [Related]
12. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia and pancreatic ductal adenocarcinoma.
Yamasaki A; Yanai K; Onishi H
Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
[TBL] [Abstract][Full Text] [Related]
14. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
15. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
Liang C; Shi S; Qin Y; Meng Q; Hua J; Hu Q; Ji S; Zhang B; Xu J; Yu XJ
Gut; 2020 May; 69(5):888-900. PubMed ID: 31611300
[TBL] [Abstract][Full Text] [Related]
16. The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer.
Ohara Y; Valenzuela P; Hussain SP
Trends Cancer; 2022 Jul; 8(7):556-569. PubMed ID: 35525794
[TBL] [Abstract][Full Text] [Related]
17. The biological underpinnings of therapeutic resistance in pancreatic cancer.
Beatty GL; Werba G; Lyssiotis CA; Simeone DM
Genes Dev; 2021 Jul; 35(13-14):940-962. PubMed ID: 34117095
[TBL] [Abstract][Full Text] [Related]
18. Genetics and biology of pancreatic ductal adenocarcinoma.
Ying H; Dey P; Yao W; Kimmelman AC; Draetta GF; Maitra A; DePinho RA
Genes Dev; 2016 Feb; 30(4):355-85. PubMed ID: 26883357
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic signaling pathways in pancreatic ductal adenocarcinoma.
Agrawal R; Natarajan KN
Adv Cancer Res; 2023; 159():251-283. PubMed ID: 37268398
[TBL] [Abstract][Full Text] [Related]
20. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]